CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 13 enrolled
Drug / intervention
Minocyclinedrug
Likely dose
Minocycline 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01463384
NCT01463384Phase 2Completed
CompareCT.gov

MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy

Huntington Medical Research Institutes·interventional·Posted Nov 1, 2011·Updated Sep 25, 2014

In Brief

A Phase 2 clinical trial evaluating Minocycline for Mild Cognitive Impairment and Alzheimer's Disease. Completed, enrolled 13 participants across 1 site.

Detailed Summary

Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance imaging (MRI) and proton (1H ) and carbon 13 (13C) magnetic resonance spectroscopy (MRS). Each individual will receive minocycline oral administration for 4 weeks initially, after which MRI, MRS and neuropsychological results will be recorded. If no adverse side effects occur, subjects will continue minocycline administration for an additional 5 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Alzheimer's Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 1, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 14.7 years ago

Interventions

Minocyclinedrug

50mg, twice daily for 6 months.